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Context—Alzheimer’s disease (AD) is usually only diagnosed many years after pathology
begins. Earlier detection would allow emerging interventions to have a greater chance to preserve
healthy brain function. A rare form of Alzheimer’s disease, caused by autosomal-dominant
mutations, affects carriers with 100% certainty and at a younger age specific to their mutation.
Studying families with these mutations allows a unique investigation of the temporal sequence of
biomarker changes in Alzheimer’s disease.
Objective—To determine whether the pupil flash response (PFR), previously reported to be
altered in sporadic Alzheimer’s disease, is different in pre-symptomatic mutation carriers.
Design—Researchers blinded to participant mutation status collected pupil response data from
cognitively normal participants in the Dominantly Inherited Alzheimer's Network (DIAN) Study
during 2010–2011.
Setting—The pupil response was examined at the McCusker Alzheimer’s Research Foundation
in Perth, Western Australia.
Participants—Participants were from a single family harboring an Amyloid-Beta Precursor
Protein genetic mutation (APPGlu693Gln). Six carriers and six non-carriers were available for
pupil testing (age 43.0±8.3 years old, 2 males and 10 females, 4 with hypertension).
Main Outcome Measure—Pupil response parameter comparison between mutation carriers and
non-carriers.
Results—75% recovery time was longer in mutation carriers (p<0.0003, ROC AUC 1.000,
Sensitivity 100%, Specificity 100%) and percentage recovery 3.5 seconds after stimulus was less
in mutation carriers (p<0.006, ROC AUC 1.000, Sensitivity 100%, Specificity 100%).
Conclusions—PFR changes occur pre-symptomatically in autosomal dominant AD mutation
carriers, supporting further investigation of PFR for early detection of AD.
Keywords
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Introduction
A rare form of Alzheimer’s disease (AD)"autosomal dominant AD” (ADAD), affects
carriers of specific gene mutations with penetration approaching 100% [1]. ADAD
represents about 1% of all AD cases and can occur in people as young as 30 years of age. It
is a genetic disorder with specific mutations in primarily amyloid precursor protein (AβPP),
presenilin 1 and presenilin 2 genes known to cause the disease [1–4]. It is inherited in an
autosomal dominant manner. Children of affected individuals have a fifty-percent risk to
develop AD dementia, with a relatively predictable age at onset within each family.
Despite the difference in underlying cause and age of onset, ADAD and the more common
sporadic AD have similar neuropathologic hallmarks and clinical features [5]. Evidence
suggests that AD related pathological changes begin at least 15 years before the
symptomatic stage [6], providing a window of time in which to detect the disease early and
allow emerging therapies the chance to preserve healthy brain function. Hence, new
knowledge about the disease process in ADAD has the potential to translate into better
methods for early detection of sporadic AD.
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Biomarkers of early AD pathology (amyloid plaques and neurofibrillary tangles) are
currently being sought in order to confirm early diagnosis, before irreversible neurological
damage occurs. Early changes to vision reported in AD have motivated investigations of
biomarkers that might exist in the eye [7–9]. The pupil flash response (PFR), the response of
the pupil size to a bright flash of light, is one ocular test that has previously been reported to
be altered in sporadic AD [10–15].
Studies of families harboring known ADAD mutations provide a powerful opportunity to
investigate the temporal sequence of ocular and other AD biomarker changes during disease
progression. Studying pre-symptomatic individuals with ADAD mutations alleviates many
problems inherent in studies of pre-symptomatic sporadic AD, including uncertainty about
disease progression. In addition, the early age of onset in ADAD means that these studies
will be less confounded by age-related co-morbidities such as hypertension and cardio-
vascular disease.
Here we investigate ocular biomarkers in ADAD by utilizing the Dominantly Inherited
Alzheimer Network (DIAN) study cohort [5]. Results from the DIAN study have already
established that AD-related cerebro-spinal fluid (CSF) pathology can be detected in
mutation carriers more than two decades before their estimated age at dementia onset [6].
Studying AD biomarkers in ADAD could prove useful for the development and evaluation
of disease-modifying prevention measures in both ADAD and sporadic AD populations.
Most DIAN study participants are in the pre-symptomatic stages of the disease and hence
provide a unique means by which to investigate the time-course of biomarker changes in the
lead-up to clinical expression of the disease. Since the parental age of dementia onset within
each family is typically known, the stage of disease progression for pre-symptomatic family
members (e.g. 10 years prior to estimated age of dementia onset) can be accurately
estimated and used as a temporal reference for biomarker changes. This also enables
comparison of biomarker changes across families with different mutations and typical age of
onset.
Pupil Responses in Alzheimer’s Disease
The pupil controls retinal illumination and responds dynamically to a bright light flash by
rapidly constricting and then re-dilating. The neurotransmitters responsible for these two
processes are acetyl-choline (Ach; constriction) and norepinephrine (NE; dilation). As the
primary neurotransmitter deficit in AD is acetyl-choline [16, 17], pupil responses have
become a research topic for AD diagnosis and monitoring.
During the 1990s a number of studies investigated the influence of AD on the effects of
pharmacological drugs delivered for pupil constriction or dilation. A hypersensitive pupil
response to a cholinergic agonist (pilocarpine - constriction) or antagonist (tropicamide -
dilation) was reported for AD patients [18–27]. However, other reports were confounding
[12, 28–37], possibly due to problems with stability of eye-drop solutions and variation in
corneal penetration.
As an alternative, PFR was investigated, since it is not reliant on delivery of drugs to the
eye. Changes to a number of PFR parameters have been found in AD compared to healthy
ageing [10–15], with a single parameter (reduced “maximum constriction acceleration”)
facilitating perfect classification in one study [13]. The results from these studies are
summarized in Table 1.
The majority of the results indicate a ‘sluggish’ PFR in AD, with reduced velocities,
accelerations and constriction amplitude, and increased latencies. Similar results have been
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observed in a larger cohort by our group. The result from Ferrario et al. on increased
maximum constriction acceleration in AD stands in contrast, possibly due to different PFR
methodology and participant selection. However, consistent with other reports, constriction
latency was larger in AD. Some results indicate a faster recovery after stimulus in AD,
despite slower constriction and dilation velocities, most likely attributable to the reduced
amplitude [11, 13].
Some studies have found that Parkinson’s disease patients exhibit similar PFR changes [12,
38], hence more research is required to confirm the sensitivity and specificity of each of the
PFR parameters (or a combined panel) as a screening tool for AD. Here, we investigate the
PFR in ADAD mutation carriers, who exhibit similar neuropathological hallmarks and
clinical features as sporadic AD[5]. To the authors’ knowledge, no other study has published
results on PFR in ADAD mutation carriers.
Subjects and Methods
Participants
Participants for the PFR study were recruited from the DIAN study (DIAN, NIA U19
AG032438, JC Morris, PI) at the McCusker Foundation for AD Research, Perth, Western
Australia (www.dian-info.org, clinicaltrials.gov number NCT00869817). DIAN study
procedures are published elsewhere (Morris et. al. 2012, in press) [39] and were approved by
the Washington University Human Research Protection Office and also the Hollywood
Private Hospital Ethics Committee. All PFR experiments were approved by the Ethics
Committee of the University of Western Australia. All participants provided their written
informed consent for this study.
Exclusion criteria for the PFR study were past history of ocular operations or
ophthalmological disease, asymmetrical pupils, receiving anticholinergics, cardiac
glycosides, sympathomimetics or ophthalmic agents affecting PFR.
All participants were white Caucasians from a single family harbouring Dutch cerebral
amyloid angiopathy (hereditary cerebral hemorrhage with amyloidosis - Dutch type,
HCHWA-D). The APP 693 mutation at position 22 of the amyloid-beta fragment
(APPGlu693Gln), resulting in a glutamine for glutamic acid, was identified in the proband
and his affected sister who died at age 61 and 66 respectively, from recurrent lobar
hemorrhages in the brain. Neuritic amyloid plaques were found but neither dementia nor
cognitive decline have been diagnosed in this family, possibly due to earlier onset of
vascular pathology.
The mean paternal anticipated age of onset (AAO) is 51. All but 2 of the 12 were younger
than the parental AAO at time of PFR, and 8 of the 12 were within 15 years younger than
the parental AAO. All participants performed above the mini-mental state examination
(MMSE) [40] cut off score for dementia (>24), indicating normal cognitive function. The
mean MMSE scores were 29.0±0.9 for MC, 27.5±2.1 for NC. Participants were
neuroimaged for the presence of fibrillar brain amyloid using positron emission tomography
(PET) with Pittsburgh Compound B (PiB) [41, 42]. Results for neocortical standardized
uptake value ratio (SUVR) were calculated.
System of Pupillometry
The PFR was collected using a NeurOptics™ VIP™-200 Pupillometer. This is a
commercial, monocular device providing fully automated operation and calculation of
response parameters. The device produces a white flash stimulus and then measures the
pupil size for 5 seconds using infrared illumination. The video frame rate is 33Hz, the
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stimulus/pulse intensity is 180µW and the stimulus/pulse duration is 31 milliseconds. The
pupillometer produces diffuse light over the whole visual field.
The room was darkened for 2 minutes prior to testing. The test was practiced once before
recording, all participants performed the experiment with proper cooperation. Occasionally,
an extra trial was needed to achieve a recording without blinks or artefacts. Data was
rejected if artefacts were present. The right eye was used for all participants. The
pupillometer provided automatic calculation of the following eight parameters; resting pupil
diameter (mm), minimum pupil diameter (mm), response latency (msec), mean constriction
velocity (mm/sec), maximum constriction velocity (mm/sec), mean dilation velocity (mm/
sec), 75% recovery time (sec) and constriction percentage (%) relative to initial pupil size. A
record of the pupil's diameter as a function of time was exported from the pupillometer. Four
extra parameters (constriction amplitude (mm), maximum constriction acceleration (mm/
sec), latency to maximum constriction (sec) and percentage recovery 3.5 seconds after
stimulus (%)) were calculated from the exported PFR data. PFR trials with artefacts or
excessive blinking were discarded. A computer algorithm was used to remove minor blinks.
Genetic Analysis
Genotyping for familial AD mutations and APOE isoforms was performed by the DIAN
Genetics Core. Ambient blood samples were shipped from the DIAN performance sites to
both the National Cell Repository for Alzheimer’s Disease (NCRAD) and the DIAN
Genetics Core at Washington University. DNA was extracted from blood at both sites using
standard procedures. DNA sequencing of AβPP, presenilin 1 and presenilin 2 genes was
performed by DIAN Genetics Core personnel, using Sanger sequencing methods on an ABI
3130xl, to determine the presence/absence of a disease-causing mutation [43]. APOE
genotyping was performed using an ABI predesigned real time TaqMan assay “rs7412 &
rs429358” according to the manufacturer’s protocol (ABI, Foster City, CA). DNA
fingerprinting was performed with the Cell ID kit, using short tandem repeat (STR) analysis
of 10 specific loci in the human genome, nine STR loci and Amelogenin for gender
identification (Promega #G9500, Madison, WI) in order to confirm that DNA samples
obtained by NCRAD and the DIAN Genetics Core were from the same individual. DNA
sequencing, fingerprinting and genotyping was performed on DNA from NCRAD and the
DIAN Genetics Core in parallel for each individual, and the data were compared for quality
control purposes. All individuals included in this analysis have 100% concordant data for
each DNA sample.
Statistical analysis
Demographic analysis between mutation carrier (MC) and non-carrier (NC) groups was
performed using a chi square (χ2) test for categorical variables (gender and APOE ϵ4 carrier
status), and analysis of variance (ANOVA) for the continuous variables (age and MMSE).
ANOVA was also used to compare SUVR between groups.
PFR scores for the MC and NC groups were compared using analysis of variance
(ANCOVA) correcting for age, gender and APOE ϵ4 status. Since 12 PFR parameters were
analysed, the possibility of false positive results was minimised using the false discovery
rate (FDR) method [44].
Receiver-operating characteristic (ROC) curve analysis was also performed to further
illustrate the classification accuracy of the PFR parameters. The area under the curve (AUC)
of the ROC curves was estimated, an AUC of 1 indicates perfect classification ability into
MC or NC, whereas an AUC near 0.5 indicates poor (random) classification ability. All
statistical analyses were conducted in XLstat 2011 (Microsoft Excel).
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The demographic characteristics of the MC and NC groups are described in Table 2. Groups
were not significantly different in age, gender or APOE ϵ4 carrier status. Neocortical plaque
burden (Standardised Uptake Value Ratio, SUVR) was higher in the MC group (1.23±0.08)
than the NC group (1.08±0.04) (p=0.004).
The 75% recovery time (75%RT) was larger in mutation carriers (p=0.0003). Percentage
recovery 3.5 seconds after stimulus (PR3.5) was smaller in mutation carriers (p=0.006) (see
Figure 1). This slower or ‘sluggish’ PFR trend was also observed in mutation carriers for
mean constriction velocity, max constriction velocity, mean dilation velocity and max
constriction acceleration, but did not reach statistical significance. Confounders (age, gender
and APOE ϵ4 carrier status) were not significant in the ANCOVA models for 75%RT and
PR3.5. Confounders were not significant for other PFR parameters with the exception of
constriction amplitude which was smaller in APOE ϵ4 carriers (p<0.0001) and in males
(p<0.0001).
Both the 75%RT and PR3.5 parameters provided perfect classification of mutation carriers
vs non-carriers (sensitivity=100%, specificity=100%) in this cohort. Receiver operator
characteristic (ROC) area under the curve (AUC) was thus 1.0 for both parameters (75%RT:
95%CI=0.84–1.00, p<0.0001; PR3.5: 95%CI=0.84–1.00, p<0.0001). The effect of estimated
years to onset of symptoms (EYO = AAO - age) on 75%RT and PR3.5 was then
investigated to explore possible changes in these parameters as part of the temporal
sequence of biomarker changes during disease progress. The mean EYO was 5.0±5.9 for
MC and for 11.2±9.5 for NC. No evidence of temporal relationships in these PFR
parameters was found.
DISCUSSION
We provide evidence from pupil flash response (PFR) testing that carriers of the
APPGlu693Gln mutation exhibit slower recovery from pupil flash response, with longer
75% recovery time and smaller percentage recovery 3.5 seconds after stimulus, than non-
carriers in the same family. The parameter ‘75% recovery time’ describes the time taken,
after constriction to minimum pupil size, to recover 75% of the constriction amplitude
through re-dilation. The parameter ‘percentage recovery after 3.5 seconds’ refers to the
percentage of the constriction amplitude recovered by re-dilation at time 3.5 seconds after
stimulus. Both parameters are measures of the recovery time for the pupil after flash
stimulus.
A ‘sluggish’ PFR has previously been reported in sporadic AD [10–13], with reduced
resting pupil size, amplitude of constriction and reduced velocity and acceleration of the
pupil size. Despite reduced constriction and dilation velocities, some of these studies
reported a quicker recovery after PFR stimulus in sporadic AD. This is likely due to the
overwhelmingly reduced amplitude of the response. The present study found non-significant
trends for reduced mean constriction velocity, maximum constriction velocity, mean dilation
velocity and maximum constriction acceleration in mutation carriers. Statistically significant
results were found for increased ‘75% recovery time’ and reduced ‘percentage recovery
after 3.5 seconds’ in mutation carriers. APPGlu693Gln mutation carriers appear to exhibit
the sporadic-AD trends for reduced pupil velocity, but not reduced amplitude, resulting in a
significantly slower recovery from stimulus.
The study of families with ADAD mutations provides three major benefits over studies into
sporadic AD. Firstly, mutation carriers progress to disease with 100% certainty and at a well
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defined age-range. Hence, although all participants in the present study were pre-
symptomatic, genetic testing enabled identification of those destined to progress to disease.
Secondly, a typically younger age of onset (about 51 years for the present analysis), usually
results in fewer confounds due to age-related medical co-morbidities. However, in the
present study we still observed 2 individuals with hypertension in each group. Thirdly,
utilizing within-family comparisons reduces the chance of other genetic influences.
Most families in the DIAN study have genetic mutations that result in AD dementia. Aβ
deposition, as measured by positron-emission tomography with Pittsburgh compound B
(PET-PiB), has been found to be higher in mutation carriers in the DIAN cohort, up to 15
years before expected symptom onset [6]. However, the ADAD mutation investigated in the
present study is a mutation of the Amyloid Precursor Protein (APP) at position 22 of the Aβ
fragment (APPGlu693Gln), replacing glutamic acid with glutamine. Mutations in this region
of APP are associated with cerebral amyloid angiopathy (CAA) and ultimately cerebral
hemorrhage. Indeed both the proband and his sister exhibited CAA and recurrent lobar
hemorrhages in the brain, but neuritic amyloid plaques were also found, indicating ADAD
pathology may also result from this mutation. PET-PiB imaging results from the participants
in the present PFR study demonstrated that the mutation carriers had higher SUVR
(1.23±0.08) than non-carriers (1.08±0.04) (p=0.004), although no participants were
categorized as high-SUVR (SUVR>1.5). Neither dementia nor cognitive decline has been
observed in this family, possibly due to earlier onset of CAA and fatal cerebral
hemorrhages.
Despite the difference in underlying cause and age of onset, ADAD and sporadic AD have
similar neuropathologic hallmarks and clinical features [5]. The present results indicate that
PFR changes may occur in the early pathogenic but pre-symptomatic stages of CAA or
ADAD. The lack of correlation between the PFR parameters and estimated years to onset
(EYO) may indicate that PFR changes occur early and subsequently stabilize over the EYO
range of this cohort, but larger cohorts will be required to investigate this hypothesis. The
major limitation of this study is the relatively small number of subjects studied, however the
results support further investigation with larger cohorts and other ADAD mutations.
PFR changes in AD are considered to be due to either degeneration in pupil-control relays in
the midbrain or cholinergic deficits in the peripheral parasympathetic pathway. Mechanisms
by which CAA could impact on PFR could also include damage to pupil-control relays in
the midbrain. As changes to pupil response have now been reported in both sporadic AD and
APPGlu693Gln mutation carriers, PFR deserves further investigation as a useful adjunct to
assist the diagnosis of early AD. PFR may also be useful in monitoring CAA or AD for
management of risk factors and treatment.
References
1. Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, et al. Alzheimer's disease
associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet. 1996 Jul;
5(7):985–988. [PubMed: 8817335]
2. Campion D, Flaman JM, Brice A, Hannequin D, Dubois B, Martin C, et al. Mutations of the
presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet. 1995 Dec;
4(12):2373–2377. [PubMed: 8634712]
3. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a
missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature.
1991 Feb 21; 349(6311):704–706. [PubMed: 1671712]
4. Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated
with hereditary Alzheimer's disease. Science. 1991 Oct 4; 254(5028):97–99. [PubMed: 1925564]
Frost et al. Page 7













5. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-
dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.
Alzheimers Res Ther. 2011; 3(1):1. [PubMed: 21211070]
6. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and Biomarker
Changes in Dominantly Inherited Alzheimer's Disease. N Engl J Med. 2012 Jul 11.
7. Katz B, Rimmer S. Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol. 1989
Jul-Aug;34(1):31–43. [PubMed: 2678551]
8. Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ. Assessment of visual impairment in
patients with Alzheimer's disease. Am J Ophthalmol. 1987 Aug 15; 104(2):113–120. [PubMed:
3618708]
9. Frost S, Martins RN, Kanagasingam Y. Ocular biomarkers for early detection of Alzheimer's
disease. J Alzheimers Dis. 2010; 22(1):1–16. [PubMed: 20847434]
10. Fotiou F, Fountoulakis KN, Tsolaki M, Goulas A, Palikaras A. Changes in pupil reaction to light in
Alzheimer's disease patients: a preliminary report. Int J Psychophysiol. 2000 Jul; 37(1):111–120.
[PubMed: 10828379]
11. Prettyman R, Bitsios P, Szabadi E. Altered pupillary size and darkness and light reflexes in
Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1997 Jun; 62(6):665–668. [PubMed:
9219763]
12. Granholm E, Morris S, Galasko D, Shults C, Rogers E, Vukov B. Tropicamide effects on pupil size
and pupillary light reflexes in Alzheimer's and Parkinson's disease. Int J Psychophysiol. 2003 Feb;
47(2):95–115. [PubMed: 12568941]
13. Fotiou DF, Brozou CG, Haidich AB, Tsiptsios D, Nakou M, Kabitsi A, et al. Pupil reaction to light
in Alzheimer's disease: evaluation of pupil size changes and mobility. Aging Clin Exp Res. 2007
Oct; 19(5):364–371. [PubMed: 18007114]
14. Ferrario E, Molaschi M, Villa L, Varetto O, Bogetto C, Nuzzi R. Is videopupillography useful in
the diagnosis of Alzheimer's disease? Neurology. 1998 Mar; 50(3):642–644. [PubMed: 9521249]
15. Tales A, Troscianko T, Lush D, Haworth J, Wilcock GK, Butler SR. The pupillary light reflex in
aging and Alzheimer's disease. Aging (Milano). 2001 Dec; 13(6):473–478. [PubMed: 11845975]
16. Herholz K, Weisenbach S, Zundorf G, Lenz O, Schroder H, Bauer B, et al. In vivo study of
acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer
disease. Neuroimage. 2004 Jan; 21(1):136–143. [PubMed: 14741650]
17. Tohgi H, Abe T, Hashiguchi K, Saheki M, Takahashi S. Remarkable reduction in acetylcholine
concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci
Lett. 1994 Aug 15; 177(1–2):139–142. [PubMed: 7824166]
18. Scinto LF, Daffner KR, Dressler D, Ransil BI, Rentz D, Weintraub S, et al. A potential
noninvasive neurobiological test for Alzheimer's disease. Science. 1994 Nov 11; 266(5187):1051–
1054. [PubMed: 7973660]
19. Idiaquez J, Alvarez G, Villagra R, San Martin RA. Cholinergic supersensitivity of the iris in
Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1994 Dec; 57(12):1544–1545. [PubMed:
7798991]
20. Pomara N, Sitaram N. Detecting Alzheimer's disease. Science. 1995 Mar 17; 267(5204):1579–
1580. author reply 80-1. [PubMed: 7886438]
21. Iijima A, Haida M, Ishikawa N, Ueno A, Minamitani H, Shinohara Y. Reevaluation of tropicamide
in the pupillary response test for Alzheimer's disease. Neurobiol Aging. 2003 Oct; 24(6):789–796.
[PubMed: 12927761]
22. Gomez-Tortosa E, del Barrio A, Jimenez-Alfaro I. Pupil response to tropicamide in Alzheimer's
disease and other neurodegenerative disorders. Acta Neurol Scand. 1996 Aug; 94(2):104–109.
[PubMed: 8891054]
23. Grunberger J, Linzmayer L, Walter H, Rainer M, Masching A, Pezawas L, et al. Receptor test
(pupillary dilatation after application of 0.01% tropicamide solution) and determination of central
nervous activation (Fourier analysis of pupillary oscillations) in patients with Alzheimer's disease.
Neuropsychobiology. 1999; 40(1):40–46. [PubMed: 10420100]
Frost et al. Page 8













24. Kalman J, Kanka A, Magloczky E, Szoke A, Jardanhazy T, Janka Z. Increased mydriatic response
to tropicamide is a sign of cholinergic hypersensitivity but not specific to late-onset sporadic type
of Alzheimer's dementia. Biol Psychiatry. 1997 Apr 15; 41(8):909–911. [PubMed: 9099419]
25. Robles A, Tourino R, Sesar A, Suarez P, Noya M. [Experience with pupil tropicamide test in
Alzheimer's disease]. Rev Neurol. 1996 Jan; 24(125):65–68. [PubMed: 8852002]
26. Kono K, Miyao M, Ishihara S, Takagi A, Ikari H, Suzuki Y, et al. [Hypersensitivity in the pupil
dilation response to a cholinergic antagonist in patients with Alzheimer's disease and Down's
syndrome]. Nippon Ronen Igakkai Zasshi. 1996 Nov; 33(11):829–834. [PubMed: 8997102]
27. Arai H, Terajima M, Nakagawa T, Higuchi S, Mochizuki H, Sasaki H. Pupil dilatation assay by
tropicamide is modulated by apolipoprotein E epsilon 4 allele dosage in Alzheimer's disease.
Neuroreport. 1996 Mar 22; 7(4):918–920. [PubMed: 8724673]
28. Kardon RH. Drop the Alzheimer's drop test. Neurology. 1998 Mar; 50(3):588–591. [PubMed:
9521239]
29. Caputo L, Casartelli M, Perrone C, Santori M, Annoni G, Vergani C. The 'eye test' in recognition
of late-onset Alzheimer's disease. Arch Gerontol Geriatr. 1998 Sep-Oct;27(2):171–177. [PubMed:
18653162]
30. FitzSimon JS, Waring SC, Kokmen E, McLaren JW, Brubaker RF. Response of the pupil to
tropicamide is not a reliable test for Alzheimer disease. Arch Neurol. 1997 Feb; 54(2):155–159.
[PubMed: 9041856]
31. Fridh M, Havelius U, Elofsson G, Hindfelt B. The pupillary response to tropicamide in
Alzheimer's disease. Acta Ophthalmol Scand. 1996 Jun; 74(3):276–279. [PubMed: 8828726]
32. Growdon JH, Graefe K, Tennis M, Hayden D, Schoenfeld D, Wray SH. Pupil dilation to
tropicamide is not specific for Alzheimer disease. Arch Neurol. 1997 Jul; 54(7):841–844.
[PubMed: 9236572]
33. Kurz A, Marquard R, Fremke S, Leipert KP. Pupil dilation response to tropicamide: a biological
test for Alzheimer's disease? Pharmacopsychiatry. 1997 Jan; 30(1):12–15. [PubMed: 9065964]
34. Marx JL, Kumar SR, Thach AB, Kiat-Winarko T, Frambach DA. Detecting Alzheimer's disease.
Science. 1995 Mar 17.267(5204):1577. author reply 80-1. [PubMed: 7741897]
35. Reitner A, Baumgartner I, Thuile C, Baradaran Dilmaghani R, Ergun E, Kaminski S, et al. The
mydriatic effect of tropicamide and its diagnostic use in Alzheimer's disease. Vision Res. 1997
Jan; 37(1):165–168. [PubMed: 9068838]
36. Loupe DN, Newman NJ, Green RC, Lynn MJ, KK WI, Geis TC, et al. Pupillary response to
tropicamide in patients with Alzheimer disease. Ophthalmology. 1996 Mar; 103(3):495–503.
[PubMed: 8600428]
37. Treloar AJ, Assin M, Macdonald AJ. Pupillary response to topical tropicamide as a marker for
Alzheimer's disease. Br J Clin Pharmacol. 1996 Mar; 41(3):256–257. [PubMed: 8866930]
38. Fotiou DF, Stergiou V, Tsiptsios D, Lithari C, Nakou M, Karlovasitou A. Cholinergic deficiency in
Alzheimer's and Parkinson's disease: Evaluation with pupillometry. International Journal of
Psychophysiology. 2009 Aug; 73(2):143–149. [PubMed: 19414041]
39. Morris. Developing an international network for Alzheimer research. Clinical Investigation. In
press.
40. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the
cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov; 12(3):189–198. [PubMed:
1202204]
41. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid
in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004 Mar; 55(3):306–319.
[PubMed: 14991808]
42. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al.
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of
amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005 Nov
16; 25(46):10598–10606. [PubMed: 16291932]
43. Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, et al. Extreme cerebrospinal
fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation.
Ann Neurol. 2007 May; 61(5):446–453. [PubMed: 17366635]
Frost et al. Page 9













44. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful
Approach to Multiple Testing. J Roy Stat Soc B Met. 1995; 57(1):289–300.
Frost et al. Page 10














Difference in (A) 75% Recovery Time and (B) Percentage recovery 3.5 seconds after
stimulus, between 6 mutation carriers and 6 non-carriers from the same family harboring an
APP ADAD mutation.
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Table 2
Demographic characteristics of the mutation carrier and non-carrier groups.
Mutation Carriers Non-Carriers p
Number of Participants: [N] 6 6
Age: Years [mean (SD)] 46.0 ± 5.7 40.0 ± 10.0 0.229
Gender; Males: [N (%)] 5 (83%) 5 (83%) 1.000
Hypertension: [N (%)] 2 (33.3%) 2 (33.3%) 1.000
APOE ϵ4 Carrier: [N (%)] 2 (33.3%) 1 (16.6%) 0.512
MMSE: [mean ± SD] 29.0 ± 0.9 27.5 ± 2.1 0.135
SUVR: [mean ± SD] 1.23 ± 0.08 1.08 ± 0.04 0.004
Curr Alzheimer Res. Author manuscript; available in PMC 2014 January 02.
